Wilson Therapeutics hosts Capital Markets Day today at 13:30 CET/08:30 EDT
Wilson Therapeutics (publ) will host a Capital Markets Day in Stockholm today, March 21, 2018 for investors, analysts and media. The program will include an in-depth discussion on Wilson Disease and the company’s candidate drug, WTX101, currently in Phase 3 development for Wilson Disease. During the event, pre-clinical data, data from the company’s Phase 2 study and the design of the Phase 3 study will be described further. Furthermore, the company’s market analysis and commercial planning will be presented. Members from the senior management team will be joined by Dr. Frederick